Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
05/08/2026
According to Reuters: Sources say Lockheed Martin (LMT.N) is negotiating to procure U.S. domestic scandium supplies from NioCorp Developments, as well as germanium supplies from Teck Resources and 5N Plus.
Latest
2 m ago
Thorne has reached a final acquisition agreement with Procter & Gamble (PG.N).
2 m ago
Market news: The acquisition deal by JPMorgan for the Antin business is expected to bring Idex's enterprise value (including debt) to approximately 3.8 billion, with the transaction potentially announced in the coming days.
2 m ago
US dollar bond fluctuations | The price of Three Gorges Group YANTZE 2.15 09/22/30 rose by 1.147% to 91.658.
2 m ago
Night trading futures closing
3 m ago
Novo Nordisk (NVO.N) raised its earnings forecast for the second time this year due to an increased sales expectation for its obesity and diabetes drugs. Novo Nordisk stated that the adjusted operating profit for the second quarter of 2026 would be 33.389 billion Danish kroner, raising its outlook for the entire year. The largest expected decline in sales and profits this year is anticipated to be 6%, whereas the company had previously estimated that, at constant exchange rates, the decline could reach up to 12%. Novo Nordisk is competing with its rival Eli Lilly (LLY.N) in the obesity market. According to forecasts, this market is expected to grow to $120 billion annually by 2030.
See all latest